The 15-Valent Pneumococcal Vaccine Provides Effective Protection Against Severe Bacterial Diseases The 15-valent pneumococcal vaccine effectively protects against severe diseases caused by bacteria, including pneumonia (lung infection), meningitis (meningeal infection), and acute otitis media (middle ear infection). This vaccine is designed to provide optimal protection for infants and young children. It contains purified capsular polysaccharides from pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F, all conjugated to the CRM197 carrier protein. Eligible Age for Vaccination Individuals aged 6 weeks and older. Vaccination Schedule for Lifelong Protection Under 7 months: A total of 3 doses, administered at 2, 4, and 12 months of age. 7-11 months: A total of 3 doses, with the first and second doses spaced 1 month apart, and the second and third doses spaced 2 months apart. The third dose should be administered after the child turns 12 months. 12-23 months: 2 doses are required, with at least 2 months between doses. Aged 2 years and older: A single dose is sufficient for lifelong protection. Note: Since July 2019, the Maternal and Child Health Centres under the Department of Health have implemented an updated 3-dose vaccination schedule for eligible children born on or after January 1, 2019. These children will no longer receive the PCV13 vaccine during the six-month visits at the Maternal and Child Health Centres. If needed, parents may consider scheduling a fourth dose when their child is 6 months old. Contraindications/Side Effects Individuals with a history of severe allergic reactions to any component of the vaccine or who have previously received any 13-valent pneumococcal vaccine (Prevenar 13). Infants under 6 weeks of age. Individuals with bleeding disorders or those taking anticoagulants. Individuals with a fever at the time of their appointment should postpone vaccination until they have recovered.